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Relapse in schizophrenia remains common, despite its
adverse consequences. Discontinuation of antipsychotic
medication is a strong predictor of relapse in patients with
schizophrenia. However, even when treatment with con-
ventional antipsychotic drugs is continued, relapse still
occurs in 30–50% of patients each year. The purpose of
this study was to determine whether risk of relapse and
residual psychopathology could be reduced and cognition
and quality of life improved, by switching clinically stable
subjects with schizophrenia from their usual antipsy-
chotic drug to either risperidone (1–8 mg/day) or
haloperidol (2.5–20 mg/day) for a minimum of one year.
Criteria for relapse were psychiatric hospitalization, need
for an increase in the level of psychiatric care with a 25%
increase in PANSS score, a CGI change score of 6, deliber-
ate self-injury, suicidal/homicidal ideation or injury to
others/property damage. The PANSS was used to assess
residual psychopathology. Lehmann's Quality of Life
Interview was used to assess quality of life and a battery of
cognitive tests featuring verbal memory was used to assess
cognition.
The mean time to relapse in risperidone-treated and
haloperidol-treated patients was 452 days and 391 days,
respectively (p = 0.001). From baseline to final assess-
ment, mean total PANSS and sub-scale scores for positive
symptoms, negative symptoms, disorganized thoughts,
uncontrolled hostility/excitement and anxiety/depression
all significantly favored risperidone over haloperidol.
Treatment with risperidone was also associated with sig-
nificant increases in almost all components of quality of
life and cognition (verbal memory) as compared to
haloperidol. Finally, adverse events of insomnia, psycho-
sis, somnolence, agitation hyperkinesia and EPS were
more frequent in the haloperidol-treated patients than in
the risperidione-treated patients. Compliance was very
high in both groups of patients (more than 95% of all
drug doses were taken correctly).
These results suggest that the outcome of schizoprhenia
can be altered by the selection of antipsychotic drug. Spe-
cifically, risperidone as compared to haloperidol reduced
the rate of relapse and residual psychopathology and
improved cognition and quality of life in patients with
schizophrenia at doses commonly used in clinical prac-
tice. These findings enhance the body of evidence that
novel antipsychotics, such as risperidone, optimize long-
term outcomes in schizophrenia.
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